We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
Read MoreHide Full Article
Key Takeaways
AbbVie's oncology segment is projected to reach $1.71B in Q3 sales, up nearly 2% from last year.
Strong Venclexta, Epkinly and Elahere sales may balance ongoing weakness in Imbruvica.
New lung cancer drug Emrelis, approved in May, is expected to contribute modest early sales.
AbbVie (ABBV - Free Report) has built a substantial oncology franchise in recent years. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. Its latest offerings include Epkinly (for lymphoma), Elahere (for ovarian cancer), and, most recently, Emrelis (for lung cancer), bringing the total to five oncology therapies.
Sales from the oncology segment accounted for over 11% of AbbVie’s first-half 2025 revenues, which grew 5% year over year. Investors will be keen to know how its oncology segment performed in the third quarter when the company announces results on Oct. 31.
Our model estimates that third-quarter 2025 sales for the overall oncology segment will be $1.71 billion, representing nearly 2% year-over-year growth. While Venclexta, Epkinly and Elahere are likely to have contributed to growth during the quarter, these gains were likely partially offset by the continued decline in Imbruvica sales amid rising competition from novel oral therapies. As Emrelis was approved in mid-May, we expect AbbVie to record modest revenues from the drug’s sales during the quarter.
Though AbbVie’s oncology portfolio is contributing meaningfully, investor focus will largely remain on the company’s immunology franchise, which houses three flagship drugs, namely Humira, Rinvoq and Skyrizi.
For AstraZeneca, oncology sales now account for nearly 43% of total revenues. Sales in its oncology segment rose 11% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 48% of Merck’s total revenues in the first half of 2025.
Pfizer’s first-half 2025 oncology revenues grew 9% on an operational basis, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for over 25% of Pfizer’s total revenues.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings
Key Takeaways
AbbVie (ABBV - Free Report) has built a substantial oncology franchise in recent years. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the company has expanded its offerings into solid tumors. Its latest offerings include Epkinly (for lymphoma), Elahere (for ovarian cancer), and, most recently, Emrelis (for lung cancer), bringing the total to five oncology therapies.
Sales from the oncology segment accounted for over 11% of AbbVie’s first-half 2025 revenues, which grew 5% year over year. Investors will be keen to know how its oncology segment performed in the third quarter when the company announces results on Oct. 31.
Our model estimates that third-quarter 2025 sales for the overall oncology segment will be $1.71 billion, representing nearly 2% year-over-year growth. While Venclexta, Epkinly and Elahere are likely to have contributed to growth during the quarter, these gains were likely partially offset by the continued decline in Imbruvica sales amid rising competition from novel oral therapies. As Emrelis was approved in mid-May, we expect AbbVie to record modest revenues from the drug’s sales during the quarter.
Though AbbVie’s oncology portfolio is contributing meaningfully, investor focus will largely remain on the company’s immunology franchise, which houses three flagship drugs, namely Humira, Rinvoq and Skyrizi.
Competition in the Oncology Space
Other bigger players in the oncology space are AstraZeneca (AZN - Free Report) , Merck (MRK - Free Report) and Pfizer (PFE - Free Report) .
For AstraZeneca, oncology sales now account for nearly 43% of total revenues. Sales in its oncology segment rose 11% in the first half of 2025. AstraZeneca’s strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck’s key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 48% of Merck’s total revenues in the first half of 2025.
Pfizer’s first-half 2025 oncology revenues grew 9% on an operational basis, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. The segment now accounts for over 25% of Pfizer’s total revenues.